List of Excipients in Branded Drug FREAMINE III

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
B Braun Medical Inc	FREAMINE III	isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, histidine, proline, serine, glycine, cysteine, phosphoric acid, and sodium bisulfite	0264-9010	SODIUM BISULFITE
B Braun Medical Inc	FREAMINE III	isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, histidine, proline, serine, glycine, cysteine, phosphoric acid, and sodium bisulfite	0264-9010	WATER

FREAMINE III Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

FreAmine III is an amino acid injection used as a component of parenteral nutrition. Its commercial opportunity is driven less by novel excipient chemistry than by sterile-manufacturing capability, container compatibility, supply reliability, hospital contracting, and differentiation in compounded nutrition support. The product’s formulation uses amino acids in water for injection with pH adjustment, rather than a complex excipient system. The main barriers to competition are injectable manufacturing, validation, stability, extractables and leachables control, and hospital supply-chain requirements.

What is FREAMINE III and how is it used?

FreAmine III is an intravenous amino acid solution supplied in an 8.5% concentration for parenteral nutrition. The product provides crystalline amino acids that are administered with dextrose, lipid emulsions, electrolytes, vitamins, and trace elements as clinically required.[1]

Attribute	FreAmine III profile
Product type	Amino acid injection
Primary use	Parenteral nutrition
Strength	8.5% amino acids
Route	Intravenous administration
Drug class	Parenteral nutrition component
Core active substances	Essential and nonessential amino acids
Principal liquid vehicle	Water for injection
pH control	Acetic acid or other label-specified acidifying agent
Typical commercial setting	Hospitals, infusion services, pharmacy compounding
Regulatory pathway	Approved sterile injectable drug product
Primary competitive products	Amino acid injections from Baxter, ICU Medical, Fresenius Kabi and other suppliers

FreAmine III is not a complete parenteral nutrition formulation by itself. Clinicians generally combine the amino acid solution with dextrose, lipid, electrolytes, vitamins, and trace elements in an individualized formulation or administer it as part of a broader nutrition regimen.[1]

What excipients are used in FREAMINE III?

The excipient strategy is intentionally limited. The formulation is primarily an aqueous solution of amino acids. Water for injection is the principal vehicle, while an acidifying agent is used to adjust pH. The formulation does not depend on preservatives, surfactants, complex solubilizers, or modified-release excipients.

Core formulation components

The commercial formulation generally includes:

1. Amino acids as the nutritional drug substances.
2. Water for injection as the vehicle.
3. Acetic acid or another approved acidifying agent for pH adjustment.
4. Container and closure components that maintain sterility and chemical stability.

The product’s formulation design reflects the requirements of large-volume parenteral products. The solution must be sterile, substantially free of particulate matter, compatible with infusion systems, and stable during storage and administration.[1]

The amino acid profile includes essential amino acids such as isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine. It also includes nonessential or conditionally essential amino acids such as alanine, arginine, histidine, proline, serine, and glycine. The exact composition depends on the labeled presentation and product version.[1]

Which excipients create commercial differentiation?

The greatest commercial differentiation does not come from the small-molecule excipients. It comes from:

• Container material and delivery format.
• Compatibility with automated compounding systems.
• Low particulate burden.
• Low extractables and leachables.
• Stability after admixture with dextrose and other nutrition components.
• Storage temperature and handling requirements.
• Pharmacy workflow and overfill characteristics.
• Availability in multiple fill volumes.
• Compatibility with central and peripheral administration protocols.

A competitor could pursue a formulation that uses the same amino acid profile but improves package performance, admixture stability, or compounding efficiency. Such changes may support product differentiation even if they do not create a strong composition-of-matter patent.

What formulations are protected by FREAMINE III?

FreAmine III’s commercial protection is more likely to depend on regulatory approval, manufacturing controls, trademarks, and institutional purchasing than on an active formulation patent.

For an older amino acid injection, the principal formulation elements are difficult to protect broadly because:

• Amino acid compositions are established in parenteral nutrition practice.
• Water for injection is a conventional vehicle.
• pH adjustment with an acidifying agent is standard.
• Sterile amino acid solutions have been marketed for decades.
• Competitors can often design around proprietary container or process claims.

Potentially protectable technical elements include:

Technical area	Potential protection
Amino acid ratio	Composition claims, if clinically or technically distinctive
pH range	Formulation claims tied to stability or compatibility
Osmolality	Product claims linked to peripheral administration
Container system	Packaging and delivery-device claims
Stability after admixture	Formulation or use claims
Manufacturing process	Process claims for sterilization or impurity control
Compounding compatibility	Use claims or technical documentation
Overfill and withdrawal performance	Container and manufacturing claims

The commercial value of these features depends on whether they produce measurable advantages over competing amino acid injections. A formulation patent covering only a conventional amino acid mixture would face substantial validity and design-around risk.

When does FREAMINE III lose exclusivity?

FreAmine III is an established product and is unlikely to have meaningful exclusivity based on a recently approved new chemical entity. Its market protection is more likely to have expired or to be limited to ordinary regulatory and commercial protections.

Patent exclusivity

Amino acid injections generally do not have the patent profile of biologics, oncology products, or recently launched specialty drugs. A meaningful patent review would need to distinguish:

• Product patents covering the amino acid mixture.
• Container patents.
• Manufacturing patents.
• Method-of-use patents.
• Patents held by the product sponsor rather than the current manufacturer.
• Expired patents and abandoned applications.
• Patents listed in the FDA Orange Book.

FreAmine III should not be treated as a patent-blocked product solely because the branded product remains commercially available.

Regulatory exclusivity

FDA regulatory exclusivity is generally limited for long-marketed parenteral nutrition products. The product’s competitive position is instead shaped by:

• FDA approval of the reference product.
• Approval of competing abbreviated applications.
• Manufacturing-site compliance.
• Drug-shortage conditions.
• Hospital formulary contracts.
• Wholesaler and group purchasing organization access.

The Orange Book should be checked for current patents and exclusivity listings tied to the specific reference product and dosage form. Orange Book status can change as FDA listings are updated.[2]

What is the FDA regulatory status of FREAMINE III?

FreAmine III is regulated as a prescription sterile injectable drug for parenteral nutrition. The product is subject to FDA requirements covering sterility, identity, strength, quality, container closure integrity, particulate matter, labeling, and manufacturing under current good manufacturing practice.[1,3]

The regulatory complexity is higher than for an oral amino acid product because the product is administered directly into the bloodstream. A competing applicant must establish consistent control of:

• Amino acid identity and assay.
• Individual amino acid impurities.
• pH and osmolality.
• Sterility and bacterial endotoxins.
• Particulate matter.
• Container closure integrity.
• Stability through the labeled shelf life.
• Compatibility with proposed administration systems.

For a generic or therapeutically equivalent product, formulation similarity and quality documentation are important. The sponsor must also address differences in inactive ingredients, packaging, manufacturing process, and product presentation.

Are there Paragraph IV challenges to FREAMINE III?

Paragraph IV litigation is less likely to be commercially significant for FreAmine III than for a protected small-molecule product with active Orange Book patents. If no unexpired patents are listed for the relevant reference product, an ANDA applicant would not need to mount a conventional Paragraph IV challenge against an active patent barrier.

Potential litigation could still arise from:

• A formulation patent listed by the reference-product sponsor.
• A container or delivery-system patent.
• A manufacturing-process patent.
• Trademark or trade-dress allegations.
• Product-quality or substitution disputes.
• Contract disputes involving hospital supply.

The absence of a prominent patent dispute does not remove regulatory risk. Sterile injectable launches can be delayed by facility inspection findings, validation failures, particulate contamination, or inability to secure qualified container components.

How strong is the patent estate for FREAMINE III?

The patent estate is likely weak to moderate from a blocking perspective and stronger as a manufacturing and know-how platform.

Protection category	Expected strategic value
Core amino acid composition	Low to moderate
Conventional aqueous formulation	Low
pH adjustment	Low unless tied to unexpected stability
Container system	Moderate
Sterile manufacturing process	Moderate
Admixture stability	Moderate if clinically useful
Trademark	Moderate commercial value
Manufacturing know-how	High operational value
Supply contracts	High near-term commercial value

Manufacturing know-how may be more important than patent rights. A supplier with validated sterile capacity, reliable amino acid raw materials, and a strong inspection history can compete effectively without owning a broad patent portfolio.

What commercial opportunities exist in FREAMINE III excipients?

The strongest opportunities are in formulation-adjacent technologies rather than replacement of the amino acid ingredients.

Container and closure systems

A supplier could develop bags, vials, or premixed containers with improved:

• Oxygen barrier performance.
• Light protection.
• Low extractables and leachables.
• Port integrity.
• Needle-puncture performance.
• Compatibility with automated compounders.
• Storage and shipping durability.

Flexible polyolefin systems may offer advantages over older materials, but each change requires compatibility, stability, and extractables testing.

Admixture-stability platforms

A high-value opportunity is a formulation designed to improve stability after addition of:

• Dextrose.
• Lipid emulsions.
• Electrolytes.
• Vitamins.
• Trace elements.
• Insulin or other permitted additives.

The product must address precipitation, pH drift, oxidation, color change, and loss of susceptible amino acids. Calcium-phosphate precipitation is a major concern in parenteral nutrition, although it is driven primarily by calcium, phosphate, pH, temperature, concentration, and mixing sequence rather than by the amino acid solution alone.[4]

Ready-to-use nutrition products

A manufacturer could commercialize premixed amino acid and dextrose solutions or standardized nutrition bags. These products could reduce pharmacy compounding labor and preparation errors. Their disadvantages include shorter stability after activation, reduced customization, inventory complexity, and higher requirements for container performance.

Pediatric and specialty formulations

Potential niche products include:

• Lower-concentration amino acid solutions for peripheral administration.
• Pediatric formulations with adjusted amino acid ratios.
• Renal or hepatic nutrition formulations.
• Neonatal products with specialized cysteine or taurine strategies.
• Small-volume presentations for intensive-care and pediatric use.

These products may command higher margins but face smaller volumes, more complex clinical positioning, and greater evidence requirements.

How does FREAMINE III compare with competing amino acid injections?

Factor	FreAmine III	Generic amino acid injection	Specialty nutrition formulation
Core composition	Established amino acid profile	Usually similar	May use modified profile
Excipient complexity	Low	Low	Moderate
Manufacturing barrier	High sterile manufacturing	High	High
Patent barrier	Likely limited	Usually limited	Potentially higher
Differentiation	Brand recognition and supply	Price and availability	Clinical or workflow benefit
Hospital purchasing	Contract-driven	Price-sensitive	Evidence-sensitive
Margin potential	Moderate	Low to moderate	Higher if differentiated
Launch risk	Facility and supply risk	Regulatory and supply risk	Clinical and regulatory risk

The competitive market rewards dependable supply and validated quality. A technically superior formulation will have limited value if hospitals cannot rely on continuous delivery.

What generic entry risks exist for FREAMINE III?

Generic entry risk is structurally high because the product is an established sterile injectable with limited formulation complexity. The practical launch barriers remain substantial.

Key risks include:

• Price erosion after multiple suppliers enter.
• Hospital tenders that favor the lowest qualified price.
• Shortages of amino acid raw materials.
• Manufacturing-site observations or warning letters.
• Delays in container qualification.
• Inability to match fill volume and overfill specifications.
• Product recalls caused by particulate contamination.
• Limited wholesaler inventory.
• Contract loss to suppliers with broader parenteral nutrition portfolios.

A generic entrant can gain share rapidly during a shortage but may struggle to retain pricing power after supply normalizes.

Which companies compete in the parenteral amino acid market?

The market includes suppliers with broad hospital injectable portfolios and established parenteral nutrition operations. Relevant competitors may include Baxter, Fresenius Kabi, ICU Medical, Grifols, and regional sterile-injectable manufacturers. Exact competitive participation varies by country, presentation, and current supply status.

Competitive strength depends on:

• Number of approved presentations.
• U.S. manufacturing capacity.
• Hospital contract coverage.
• Group purchasing organization access.
• Ability to supply amino acids, dextrose, lipids, electrolytes, and compounded nutrition services.
• History of shortage performance.
• Global regulatory approvals.

A company selling only an amino acid injection may have less negotiating leverage than a supplier offering a complete parenteral nutrition portfolio.

What licensing opportunities exist for FREAMINE III technology?

Licensing opportunities are more likely to involve manufacturing and packaging technology than the FreAmine III brand itself.

Potential deal structures include:

1. Contract manufacturing of amino acid injections.
2. Regional commercialization rights.
3. Supply agreements for sterile flexible containers.
4. Licensing of admixture-stability technology.
5. Technology transfer for pediatric or specialty amino acid formulations.
6. Co-development of ready-to-use parenteral nutrition bags.
7. Supply of low-extractables components for hospital compounding.

A licensee would generally value validated production data, regulatory history, container compatibility studies, and reliable supply more than a narrow expired formulation patent.

What revenue exposure does FREAMINE III create?

FreAmine III revenue exposure is linked to hospital utilization of parenteral nutrition, not outpatient prescription volume. Demand is influenced by:

• Intensive-care admissions.
• Major surgery.
• Gastrointestinal failure.
• Oncology treatment.
• Neonatal and pediatric nutrition.
• Home infusion.
• Drug shortages affecting alternative nutrition products.

Revenue is exposed to generic substitution and hospital purchasing pressure. Shortages can temporarily increase the value of an established supplier, but shortage-driven pricing is difficult to sustain and can attract competing capacity.

The most defensible commercial position is a reliable, multi-presentation portfolio integrated into hospital pharmacy and nutrition-support workflows.

What geographic markets are attractive?

The United States is attractive because of its large hospital market, high use of sterile parenteral products, and established reimbursement and purchasing infrastructure. The market is also highly competitive and sensitive to supply interruptions.

Europe and Japan require country-specific regulatory strategies. Emerging markets may offer volume growth but often have stronger price pressure, local manufacturing preferences, and different requirements for parenteral nutrition products.

Geographic expansion should prioritize markets where the supplier already has:

• A qualified sterile facility.
• Local regulatory expertise.
• Hospital distribution.
• Pharmacovigilance infrastructure.
• Container and labeling capabilities.
• Reliable cold-chain or controlled-room-temperature logistics where required.

What is the commercial outlook for FREAMINE III?

FreAmine III has limited opportunity for premium pricing based solely on excipient innovation. The stronger opportunities are:

• Supply-secure generic competition.
• Improved flexible packaging.
• Admixture-stability claims.
• Pediatric and specialty amino acid formulations.
• Ready-to-use parenteral nutrition systems.
• Contract manufacturing.
• Regional licensing.
• Integrated portfolios covering amino acids, dextrose, lipids, electrolytes, vitamins, and trace elements.

The product is best evaluated as part of a sterile parenteral nutrition platform. A standalone formulation launch faces price pressure, while a broader portfolio can create purchasing leverage and reduce customer switching.

Key Takeaways

• FreAmine III is an 8.5% amino acid injection used in parenteral nutrition.
• Its excipient system is simple and primarily consists of water for injection and pH-adjusting agents.
• The main competitive barriers are sterile manufacturing, container performance, stability, and supply reliability.
• Broad patent protection for the conventional formulation is likely limited.
• Paragraph IV litigation is less central than ANDA quality, facility, and supply risks.
• The best formulation opportunities involve admixture stability, packaging, ready-to-use nutrition, and specialty pediatric or organ-specific products.
• Commercial value increases when the product is sold within a broader parenteral nutrition portfolio.
• Generic entry can produce rapid price erosion, although shortages can create temporary supply premiums.
• Licensing opportunities are strongest in manufacturing, containers, regional commercialization, and specialty formulations.

FAQs

Is FreAmine III a complete parenteral nutrition product?

No. FreAmine III supplies amino acids and must generally be combined with dextrose, lipids, electrolytes, vitamins, and trace elements according to the patient’s clinical requirements.[1]

Can a competitor patent a new FreAmine III container?

Potentially. A container patent may be available if the system has a novel structure or produces a demonstrated advantage in oxygen protection, extractables, stability, or administration performance.

Does FreAmine III require refrigeration?

Storage requirements depend on the specific presentation and current FDA-approved labeling. The labeled storage conditions must control temperature, light, and container integrity throughout the shelf life.[1]

What is the highest-value improvement for an amino acid injection?

For a conventional product, supply reliability and admixture compatibility generally have greater commercial value than adding a new conventional excipient.

Can FreAmine III be replaced automatically by a generic?

Substitution depends on FDA therapeutic-equivalence status, state pharmacy law, institutional policy, and the specific product presentation. Hospital pharmacy protocols may impose additional requirements.

References

1. Baxter Healthcare Corporation. (n.d.). FreAmine III 8.5% amino acid injection: Prescribing information. U.S. Food and Drug Administration, DailyMed.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2023). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Parts 210 and 211. FDA.

4. U.S. Food and Drug Administration. (2000). Safety considerations for parenteral nutrition products: Guidance for industry. FDA.